A protamine-coated device for the control of heparin anticoagulation
Extracorporeal blood circulation (ECBC) is widely used during dialysis, cardiac catherization, and open heart operations.
In the United States alone more than 15 million ECBC procedures are done each year (1) (2) (3) (4) , all requiring heparin anticoagulation to prevent clotting. Such systemic heparinization, however may cause bleeding (5) . In fact, an early study by the Boston Colleborative Drug Surveillance Program on drugrelated hospital deaths has cited heparin as "responsible for a majority of drug deaths in patients who are reasonably healthy" (6) . Because of these problems a number of alternatives have been explored (7) , but none have met much success. To date, the administration of protamine following an ECBC procedure remains the only means in clinical practice of controlling the heparin-induced bleeding risks.
Protamine, a low molecular weight polycationic polypeptide, is normally obtained from fish. Because of its strong basic charge it interacts with the sulfate groups of heparin, forming tight complexes and neutralizing the anticoagulant effects. Despite being approved for clinical use, protamine is nonetheless a toxic compound (8) . Given intravenous, it may cause acute anaphylactoid reactions characterized by pulmonary vaso-and bronchoconstriction (9, 10) or severe life-threatening anaphylactic reactions (type I hypersensitivity) developed through an immunoglobulin-mediated pathway (8, (11) (12) (13) .
Systemic arterial hypotension and pulmonary artery hypertension have been noted in 4% of cases and nearly 100 deaths have been attributed to protamine (8, 12) . A recent prospective study by Weiler and coworkers suggests that the administration of protamine during cardiopulmonary bypass for heparin reversal may be a major cause of morbidity and mortality (13) . Yet thus far there has been no real alternative.
It is believed that the anaphylactoid-type of protamine response is induced by the circulating protamine-heparin complexes (9, 10) , whereas the IgGmediated, anaphylactic-type reaction is initiated through the conjugation of protamine with fixed antibody (8, (11) (12) (13) . Knowing these mechanisms, we propose an approach which would prevent both heparin and protamine induced complications (14) . The approach consists of placing a blood filter containing immobilized protamine (defined as a "protamine filter") at the distal end of an extracorporeal device where the blood re-enters the patient (Fig. 1) . The protamine filter would selectively remove the heparin after it has exerted its anticoagulant effect in the extracorporeal circuit and before it returns to the patient. It would also present the protamine-heparin complexes from entering the patient and also avoid direct contact between protamine and its antibodies fixed on the organ/tissue cells, thus minimizing toxic effects.
The feasibility of such an approach has been successfully demonstrated. A prototype protamine filter was developed by coupling protamine onto the inner walls of regenerated cellulose hollow fibers, using cyanogen bromide activation (15) . Regenerated cellulose hollow fibers, widely used in hemodialyzers, were selected because of their proven blood compatibility. A detailed, systematic investigation of variables affecting protamine immobilization was conducted in order to establish an optimized immobilizaion process (15, 16) . Using such optimized procedures, fibers containing desired amounts of immobilized protamine ranging from 5 to 20 mg protamine per gram of fiber dry weight was readily prepared (15) (16) (17) . In vitro characterization of the protamine filter showed that heparin adsorption on the protamine-bound fibers followed a Langmuir adsorption model (15) ; the amount of heparin adsorbed was dependent on both the heparin concentration in the solution and the protamine loading on the fibers. The Langmuir adsorption constant of the immobilized protamine was estimated to be 0.37 ± 0.06 mL/mg, whereas the saturation capacity of the protamine filter increased
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A time-dependent decrease in heparin removing efficiency by the protamine filter was observed both in vitro and in vivo (15, 17) , indicating that the protamine filter gradually became saturated. To maintain a continuous effective heparin removal the future system needs to consist of multiple protamine filters so that one filter is removing heparin while the others are being regenerated. Previous studies conducted in our laboratory show that the adsorbed heparin can be completely washed off by flushing the filter with a 2.0 M NaGI solution. Recently, an electrochemical heparin sensor that can rapidly (in less than 2 minutes) and precisely (with an accuracy to 0.1 unit/ml, of heparin) measure blood heparin levels was developed (18) . One could thus conceive of an automated heparin removing system in which the sensor is integrated in line with several protamine filters to direct the operating and switching of these filters.
The proposed protamine filter should reduce the risk of bleeding from heparin as well as of the potential toxic effects of protamine. This would greatly increase the safety of the EGBG procedure. With over 15 million of the procedures performed each year, the benefits of the protamine filter could be widespread.
Furthermore, a protamine filter may be able to prevent the type I protamine hypersensitivity, an important benefit considering the life-threatening nature of this response and the large number of patients at risk.
The proposed system would be most valuable during cardiopulmonary bypass and hemodialysis procedures. In cardiopulmonary bypass, due to the high level of heparin involved, protamine is routinely administered at the end of the procedure to avoid postoperative bleeding. A hypotensive response at this juncture would be most undesirable and could be avoided by using a protamine filter that neutralizes heparin and also alleviates protamine-induced adverse response.
In the routine hemodialysis heparinization is rarely a problem. In fact dialysis is sometimes done without any anticoagulation (19) . In acutely ill patients at high risk of bleeding, however, heparin-free dialysis can cause clotting in the extracorporeal circuit (20) , while even small doses of heparin may still cause bleeding (21) . The use of a protamine filter to allow for regional heparinization of the circuit but not of the patient may help in this situation.
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A. Current Extracorporeal Circulation with increasing the protamine loading on the fibers (15) . In vivo studies with dogs and a femoral arteriovenous bypass circuit as the experimental extracorpo real model showed that at a blood flow of 100 mL/ min, the protamine filter (6-7 g in dry weight) removed more than 50% of the given heparin (i.e. 100 units/ kg) with 10 minutes (17) . While rapid injection of protamine in dogs anticoagulated with heparin produced a profound change in systemic arterial blood pressure, cardiac output, mixed venous oxygen saturation, and pulmonary artery pressures, the protamine filter did not elicit any detectable hemodynamic change (17) . The protamine filter also markedly reduced the protamine-induced transient thrombocytopenic and granulocytopenic responses. White blood cell and platelet counts were reduced by less than 20% of the baseline in dogs with the protamine filter, as compared to more than 70% in dogs receiving intravenous protamine. Furthermore, hemolytic complement was reduced by only 10% in animals with the protamine filter but by 20% after intravenous protamine (17) .
From a practical standpoint, the proposed system is simple and flexible as it requires neither additional apparatus not invasive procedures. It should be well accepted since it utilizes a thoroughly evaluated medical device (e.g. hemodialyzer) and a clinically approved drug (protamine). Finally, the nonthrombogenic property created by the adsorption of heparin on a protamine-coated surface may enable one to use protamine coating to improve blood compatibility and enhance patency of other devices such a hemodialyzers, shunts, and grafts.
